Infliximab for induction and maintenance therapy for ulcerative colitis P Rutgeerts, WJ Sandborn, BG Feagan, W Reinisch, A Olson, J Johanns, ... New England Journal of Medicine 353 (23), 2462-2476, 2005 | 4816 | 2005 |
Infliximab, azathioprine, or combination therapy for Crohn's disease JF Colombel, WJ Sandborn, W Reinisch, GJ Mantzaris, A Kornbluth, ... New England journal of medicine 362 (15), 1383-1395, 2010 | 3733 | 2010 |
Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial JF Colombel, WJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, ... Gastroenterology 132 (1), 52-65, 2007 | 2796 | 2007 |
Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2771 | 2013 |
Crohn's disease DC Baumgart, WJ Sandborn The Lancet 380 (9853), 1590-1605, 2012 | 2706 | 2012 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies DC Baumgart, WJ Sandborn The Lancet 369 (9573), 1641-1657, 2007 | 2537 | 2007 |
Vedolizumab as induction and maintenance therapy for Crohn's disease WJ Sandborn, BG Feagan, P Rutgeerts, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 711-721, 2013 | 2441 | 2013 |
Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak, M Lukas, ... Gastroenterology 130 (2), 323-333, 2006 | 2158 | 2006 |
Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 1922 | 2015 |
Ustekinumab as induction and maintenance therapy for Crohn’s disease BG Feagan, WJ Sandborn, C Gasink, D Jacobstein, Y Lang, JR Friedman, ... New England journal of medicine 375 (20), 1946-1960, 2016 | 1883 | 2016 |
Tofacitinib as induction and maintenance therapy for ulcerative colitis WJ Sandborn, C Su, BE Sands, GR D’Haens, S Vermeire, S Schreiber, ... New England Journal of Medicine 376 (18), 1723-1736, 2017 | 1825 | 2017 |
STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD … D Turner, A Ricciuto, A Lewis, F D’amico, J Dhaliwal, AM Griffiths, ... Gastroenterology 160 (5), 1570-1583, 2021 | 1689 | 2021 |
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study WA Faubion Jr, EV Loftus Jr, WS Harmsen, AR Zinsmeister, WJ Sandborn Gastroenterology 121 (2), 255-260, 2001 | 1555 | 2001 |
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 C Gasche, J Scholmerich, J Brynskov, G D'Haens, SB Hanauer, EJ Irvine, ... Inflammatory bowel diseases 6 (1), 8-15, 2000 | 1542 | 2000 |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial G D'Haens, F Baert, G van Assche, P Caenepeel, P Vergauwe, ... The Lancet 371 (9613), 660-667, 2008 | 1472 | 2008 |
Stapling apparatus and methods of assembling or operating the same WJ Sandborn, E Rajan US Patent App. 13/301,294, 2012 | 1421 | 2012 |
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis WJ Sandborn, G Van Assche, W Reinisch, JF Colombel, G D’Haens, ... Gastroenterology 142 (2), 257-265. e3, 2012 | 1420 | 2012 |
Certolizumab pegol for the treatment of Crohn's disease WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball, P Rutgeerts, D Mason, ... New England journal of medicine 357 (3), 228-238, 2007 | 1417 | 2007 |
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota DA Schwartz, EV Loftus Jr, WJ Tremaine, R Panaccione, WS Harmsen, ... Gastroenterology 122 (4), 875-880, 2002 | 1330 | 2002 |
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis G D’haens, WJ Sandborn, BG Feagan, K Geboes, SB Hanauer, EJ Irvine, ... Gastroenterology 132 (2), 763-786, 2007 | 1329 | 2007 |